As pharmaceutical developers place greater emphasis on patient-centric drug design, Senopsys is marking 20 years of helping biopharmaceutical companies address one of formulation development’s practical challenges: making medicines palatable enough for patients to take as directed. The company specializes in sensory science, taste assessment, and taste-masking strategies for oral dosage forms intended for pediatric and adult populations. Its work addresses sensory barriers such as bitterness, oral irritation, unpleasant odors, and lingering aftertaste, which can affect patient acceptance and complicate treatment adherence.

Founded by Jeff Worthington, president of Senopsys, the company works with biotechnology and pharmaceutical developers to incorporate palatability considerations into formulation decisions. Its services include human sensory testing and rapid prototyping, providing information to help development teams compare formulation options and evaluate patient acceptability. “Palatability should never be the reason a medicine fails,” Worthington says.

According to the company, sensory testing can provide insights that analytical instruments alone may not capture, particularly when evaluating how a medicine is experienced by patients. These assessments can help sponsors identify formulation challenges earlier, select among potential approaches, and address acceptability concerns before they become more difficult or costly to resolve.

The issue can be particularly important for children, older adults, and patients with special needs, for whom the taste, smell, or texture of an oral medicine may influence whether a prescribed treatment is taken consistently. Poor acceptability can also create challenges in clinical studies, where an unpleasant dosage form may affect participants’ willingness to continue treatment.

Senopsys has supported formulation programs across multiple therapeutic areas and dosage forms, applying sensory data to development objectives that span clinical evaluation, regulatory considerations, and commercial product requirements. “What makes our work meaningful is the connection to the patient,” Worthington says, pointing to situations in which unpleasant taste or treatment fatigue can complicate the use of medicines.

The company’s 20-year milestone comes as patient-centric formulation design continues to receive attention across the pharmaceutical industry. For developers working with complex molecules and emerging drug modalities, the challenge is not limited to establishing safety and efficacy; the dosage form must also be practical and acceptable for its intended users.

Senopsys plans to expand its capabilities to support new modalities, dosage forms, and increasingly complex molecules. The company also aims to encourage earlier integration of sensory science into pharmaceutical development, rather than relying on taste-masking interventions only after formulation problems emerge.

For drug developers, that approach places palatability alongside other formulation considerations that can influence a product’s clinical usability and commercial potential. By assessing sensory attributes earlier in development, sponsors may be better positioned to identify acceptability issues and make informed formulation decisions before advancing a product.

For more information, visit www.senopsys.com.